Abstract. BACKGROUND: Abnormal methylation of urinary TWIST1 and NID2 conferred high sensitivity and specificity for the detection of urothelial carcinoma. OBJECTIVE: We examine the performance of the urine-based TWIST1/NID2 methylation assay with the addition of urine cytology for the detection of urothelial carcinoma. MATERIALS AND METHODS: A prospective multi-institutional study was conducted to assess the performance of a methylation assay for patients with hematuria or under surveillance for non-muscle invasive bladder cancer (NMIBC). All patients underwent cystoscopy, a methylation assay, and cytology. Receiver operator characteristic (ROC) curves were constructed for cytology alone, the methylation assay alone, and a combined model. Areas under the curve (AUC) were compared using likelihood ratio tests. RESULTS: A total of 172 patients were enrolled (37% for hematuria and 63% NMIBC). The AUC for cytology alone with equivocal cytologies positive was 0.704, and improved to 0.773 with the addition of the DNA methylation assay (p < 0.001). When the equivocal cytologies were considered negative, the AUC improved from 0.558 to 0.697 with the addition of the DNA methylation assay (p = 0.003). CONCLUSIONS: Addition of a TWIST1/NID2-based DNA methylation assay adds diagnostic value to urine cytology and the model is sensitive to the classification of equivocal cytology.
Background

1
DNA methylation is an epigenetic modification re-2 lated to many biologic processes and has been im-3 plicated in cancer etiology [1] [2] [3] [4] . In fact, aberrant 4 methylation is now considered a hallmark of can- tic tests [1] [2] [3] [5] [6] [7] . Analysis of genetic alterations has 7 proven to be effective for early cancer detection and 8 it has been suggested that aberrant methylation also 9 provides a promising method for monitoring the oc-10 currence of cancer [8] . Methylation profiling of genes 11 has been shown to be feasible using samples of voided 12 urine, due to the presence of urothelial cells in these 13 specimens [9] [10] [11] [12] . 14 Great interest has been shown in using methylation 15 assays for the detection of bladder cancer. Currently, 16 the standard for detection and surveillance of bladder 17 cancer is comprised of cystoscopy and urine cytology. 
Results
153
Originally, 222 subjects were tested with the methy-154 lation assay, and 13 of them (6% of the total cohort) 155 were withdrawn from further analysis because they 156 did not meet the β-actin amplification minimum (9 157 subjects from DUMC and 4 from EVMS). Of the re-158 maining 209 subjects, 172 (95 from DUMC and 77 159 from EVMS) received both a cystoscopy and an evalu-160 able urine cytology and were therefore candidates for 161 the current study. Overall, 37% of subjects were be-162 ing evaluated for hematuria while 63% were under-163 going surveillance for NMIBC. Of those on surveil-164 lance, 42% had a history of low-grade tumors, 36% 165 high-grade tumors, 67% with Ta, 16% T1, and 6% Tis. 166 The majority of subjects with a bladder cancer history 167 (56%) had not received BCG in the past. Positive cys-168 toscopies were noted in 24% of the cohort. The remain-169 ing characteristics of both cohorts can be found in Ta-170 ble 1. negative but a specificity that was maximized (96%).
200
As expected, the sensitivity improved greatly (71%) when the atypical/suspicious cytologies were consid-202 ered to be positive, but at the expense of a decreased 203 specificity (70%) ( Table 5 ). The accuracy of cytology 204 was therefore dramatically sensitive to the categoriza-205 tion of atypical/suspicious results, as these comprised 206 over 1/3 of the all cytology results.
201
207
The diagnostic performance of the urine methyla-208 tion assay was also assessed by smoking status, and 209 was found to perform better in smokers as shown in 210  Table 6 . The proportion of current or former smokers 211 was higher in the NMIBC (15% and 60%) cohort than 212 the hematuria cohort (9% and 48%, P < 0.001). Of 213 note, there were a larger proportion of patients in the 214 hematuria cohort that had high-grade or muscle inva-215 sive bladder cancer at biopsy, but this was not statisti-216 cally significant (P = 0.197). 
ROC curves
218
ROC curves were constructed and AUC calculated 219 to determine if the addition of the TWIST1 and 220 NID2 methylation assay could improve the accuracy 221 of cytology. Figure 1(a) shows the result when atyp-222 ical/suspicious cytologies are considered positive and 223 Fig. 1(b) when they are considered negative. The AUC 224 for the methylation assay alone was calculated as 225 0.669. The AUC of the combination of urine cytol-226 ogy and the urine methylation assay improved to 0.773 227 when atypical/suspicious results were considered posi-228 tive and improved to 0.697 when they were considered 229 negative. 
Conclusions
231
Analysis of urine for DNA methylation has shown 232 promise as a noninvasive method for diagnosis and 233 surveillance of bladder cancer. If an assay with accept-234 able accuracy is developed, it would have the potential 235 to become part of routine clinical practice, as the tech-236 nology has proven to be highly reproducible, accurate, 237 and inexpensive [33] . Several methylation assays have 238 shown higher sensitivity and specificity when com-239 pared to urine cytological analysis [23, 24, 34] . How-240 ever, thresholds for a positive test might not always be 241 transferable from the developmental stage to a "real-242 life" clinical scenario, and validation of these thresh-243 olds should be performed on a multi-institutional level. 244 Differences baseline patient characteristics that influ-245 ence the pre-test probability of bladder cancer between 246 the developmental cohorts and the general population 247 make multi-institutional external validation necessary 248 to determine the true applicability of a diagnostic test. 249 Tobacco smoke is a well-established carcinogen in-250 volved with bladder cancer [35] , and is a critical 251 factor for epigenetic modifications [36]. Breitling et 252 al. was first to discover smoking-related differential 253 DNA methylation, and since cigarette smoking is well 254 known to have an effect on DNA methylation in blad-255 der cancer [37] . A large epigenome-wide association 256 study (EWAS) discovered and validated statistically 257 significant differences in the methylation of 187 CpG 258 sites between current smokers and never smokers [38] . 259 In our cohort the methylation assay was more sensitive 260 in current smokers (78%) compared to former (56%) 261 and non-smokers (44%). This may be due to our sub-262 group of current smokers being small (23 patients in 263 total) and tending to have more abnormal cystoscopies. 264 However, there may be value in exploring this assay as 265 an enhanced screening test for subjects who are current 266 smokers. This also raises the speculation of a progres-267 sive methylation of these genes over time and whether 268 u n c o r r e c t e 
